Finerenone

• Description :

  Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM) . Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) . Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].

• Product Name Alternative :

  BAY 94-8862

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  Mineralocorticoid Receptor

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/finerenone.html

• Purity :

  99.95

• Solubility :

  DMSO : 70 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@@H]1C3=CC=C(C#N)C=C3OC)N

• Molecular Formula :

  C21H22N4O3

• Molecular Weight :

  378.42

• Precautions :

  H315, H319

• References & Citations :

  [1]Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7 (8) :1385-1403.|[2]González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [1050477-31-0]